General Information of Drug (ID: DMJGL72)

Drug Name
KW-2478 Drug Info
Synonyms
KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
PubChem CID
23116322
CAS Number
CAS 819812-04-9
TTD Drug ID
DMJGL72

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cromoglicate DM74LZK Asthma CA23 Approved [3]
Amlexanox DM0DQM5 Respiratory tract inflammation CA07 Approved [3]
NVP-AUY922 DMTYXQF Multiple myeloma 2A83 Phase 2 [4]
BIIB-021 DMPAJ41 Breast cancer 2C60-2C65 Phase 2 [5]
VER 50589 DMFLZPC Breast cancer 2C60-2C65 Phase 2 [4]
Tanespimycin DMNLQHK Breast cancer 2C60-2C65 Phase 2 [6]
Efungumab DMBHP56 Breast cancer 2C60-2C65 Phase 2 [7]
SNX-5422 DMIU0VP Haematological malignancy 2B33.Y Phase 1/2 [8]
PU3 DMJO0BP Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Debio 0932 DMWP3G1 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01063907) A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
2 Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
3 Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
4 Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
5 BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
6 Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
7 Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
8 SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
9 Clinical pipeline report, company report or official report of Debiopharm (2011).